, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortress Biotech Inc. ("Fortress" or the "Company") (NASDAQ: FBIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Fortress and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] CONTACT: Danielle Peyton Pomerantz ...

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and growth prospects during the specified Class Period from December 12, 2024, to June 30, 2025 [1][4]. Company Overview - Centene Corporation is a healthcare enterprise that provides fully integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals [3]. Allegations and Misleading Information - The lawsuit claims that Centene's management misled investors by presenting a false impression of reliable information concerning the company's projected revenue and growth, emphasizing strong enrollment rates and low morbidity levels [4]. - Contrary to these claims, the complaint alleges that there were adverse enrollment trends and worsening morbidity rates that were concealed from investors [5]. Financial Impact and Guidance Revision - On July 1, 2025, Centene withdrew its 2025 guidance, revealing disappointing findings from an internal analysis that indicated market growth across 22 states, which account for approximately 72% of its marketplace membership, was significantly below expectations [6]. - Following this announcement, Centene revised its earnings guidance downward to approximately $1.8 billion, translating to an adjusted diluted EPS of $2.75 [6]. - The stock price of Centene dropped by more than 40% after the guidance revision, resulting in substantial financial harm to investors [7].

Core Viewpoint - CPI Card Group Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and a significant stock price drop [1][3][4]. Financial Performance - On August 8, 2025, CPI reported Q2 2025 financial results that missed both revenue and earnings estimates, with a GAAP earnings-per-share of $0.04, falling short by $0.46, and revenue of $129.75 million, missing estimates by $3.21 million [3]. - The company revised its 2025 outlook, now expecting net sales growth in the low double-digit to mid-teens range, an increase from the previous mid-to-high single-digit growth forecast [3]. Stock Market Reaction - Following the announcement of the financial results, CPI's stock price dropped by $5.37 per share, or 28.83%, closing at $13.25 per share on August 8, 2025 [4]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of CPI investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Sensus Healthcare, Inc. and its officers or directors [1] Financial Performance - On August 7, 2025, Sensus reported a second quarter GAAP earnings-per-share of -$0.06, missing estimates by $0.09 [3] - The company's revenue for the second quarter was $7.3 million, reflecting a year-over-year decline of 20.7% and missing estimates by $2 million [3] - The revenue decline was primarily attributed to a lower number of units sold to a large customer, although there was some offset from growth in recurring revenue from Fair Deal Agreements [3] Stock Market Reaction - Following the financial results announcement, Sensus's stock price dropped by $1.89 per share, or 35.32%, closing at $3.46 per share on August 8, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Nutex Health Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation and Allegations - The investigation by Pomerantz LLP is focused on whether Nutex and its executives have engaged in securities fraud or other unlawful business practices [1]. - Blue Orca Capital issued a short report alleging that Nutex faces litigation risk due to its relationship with HaloMD, which has been sued for a fraudulent scheme involving insurance companies [3]. Group 2: Market Reaction - Following the publication of the Blue Orca report, Nutex's stock price fell by $11.18 per share, representing a decline of 10.05%, closing at $100.01 per share on July 22, 2025 [4].

Core Viewpoint - Albany International Corp. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q2 2025, which led to a significant drop in stock price [1][3]. Financial Performance - Albany reported non-GAAP earnings per share of $0.57 for Q2 2025, missing consensus estimates by $0.16 [3]. - The company's stock price fell by $16.77, or 23.63%, closing at $54.19 per share on July 31, 2025, following the earnings announcement [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Albany investors regarding possible securities fraud or other unlawful business practices by the company and its officers/directors [1].

Core Viewpoint - Insperity, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant decline in its financial performance and stock price [1][3]. Financial Performance - On August 1, 2025, Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline year-over-year and below analyst expectations [3]. - The company attributed its poor performance to higher-than-expected benefits costs, particularly due to rising pharmacy expenses and an increase in large insurance claims [3]. - Following the earnings announcement, Insperity's stock price dropped by $14.51, or 24.35%, closing at $45.07 per share [4]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Insperity investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Confluent, Inc. and its officers or directors, following a significant drop in the company's stock price after disappointing financial results [1][2]. Financial Performance - On July 30, 2025, Confluent announced its second-quarter financial results, revealing that consumption growth was negatively affected by ongoing optimization, with month-over-month trends lagging behind previous years [2]. - The company's stock price plummeted by $8.68 per share, or 32.86%, closing at $17.73 per share on July 31, 2025, in response to the earnings call and the CFO's comments regarding reduced usage of Confluent Cloud by an AI-native customer [2]. Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Confluent, indicating a potential class action lawsuit related to the alleged securities fraud [1]. - The firm has a long history of handling corporate, securities, and antitrust class litigation, emphasizing its commitment to fighting for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Insperity, Inc. is under investigation for potential securities fraud following a significant decline in its financial performance, which has led to a sharp drop in its stock price [1][2][3]. Financial Performance - Insperity reported adjusted earnings per share of $0.26 for Q2 2025, which was a 70% decline year-over-year and below analyst expectations [2]. - The company attributed its poor performance to higher-than-expected benefits costs, particularly due to rising pharmacy expenses and an increase in large insurance claims [2]. - Following the announcement of these results, Insperity's stock price fell by $14.51, or 24.35%, closing at $45.07 per share on August 1, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of Insperity investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Funko, Inc. and its officers or directors [1] Group 1: Company Developments - Funko announced the departure of its CEO, Cynthia Williams, effective July 5, 2025, which led to a significant stock price decline of $0.51 per share, or 10.49%, closing at $4.35 per share on July 7, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]